Furthermore, high NKG2C expression correlated with improved outcomes after PD-1 monoclonal antibody treatment, suggesting that targeting inhibitory NK receptors and promoting NKG2C-mediated responses could restore immune surveillance and improve anti-tumor immunity.106. The gene discussed is KLRC2; the disease is neoplasm.